Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Moodys

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,865,885

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,865,885
Title:MicroRNA fingerprints during human megakaryocytopoiesis
Abstract: Described herein is a pharmaceutical composition for treating a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.
Inventor(s): Croce; Carlo M. (Columbus, OH), Garzon; Ramiro (Columbus, OH), Calin; George A. (Pearland, TX)
Assignee: The Ohio State University Research Foundation (Columbus, OH)
Application Number:13/925,954
Patent Claims:1. A pharmaceutical composition for treating a subject exhibiting a cancer and/or a myeloproliferative disorder associated with overexpression of a transcription factor gene product from the homeobox gene family (HOXA1), wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of: acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), multiple myeloma (MM), and chronic myelogenous leukemia (CML), the composition comprising an effective amount of at least one miR-10a gene product and a pharmaceutically-acceptable carrier, wherein the at least one miR-10a gene product binds to, and decreases expression of, the HOXA1 gene product in the subject, wherein the at least one miR-10a gene product comprises one or more chemical modifications selected from the group consisting of: sugar modifications, backbone modifications, and combinations thereof; and wherein the subject has been diagnosed with acute myeloid leukemia (AML).

2. The pharmaceutical composition of claim 1, wherein the at least one miR-10a gene product comprises a nucleotide sequence that is complementary to a nucleotide sequence in the HOXA1 gene product.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises at least one anti-cancer agent.

4. The pharmaceutical composition of claim 3, wherein the at least one anti-cancer agent is selected from the group consisting of: cytidine arabinoside, methotrexate, vincristine, etoposide (VP-16), doxorubicin (adriamycin), cisplatin (CDDP), dexamethasone, arglabin, cyclophosphamide, sarcolysin, methylnitrosourea, fluorouracil, 5-fluorouracil (5FU), vinblastine, camptothecin, actinomycin-D, mitomycin C, hydrogen peroxide, oxaliplatin, irinotecan, topotecan, leucovorin, carmustine, streptozocin, CPT-11, taxol, tamoxifen, dacarbazine, rituximab, daunorubicin, 1-.beta.-D-arabinofuranosylcytosine, imatinib, fludarabine, docetaxel, and FOLFOX4.

5. The pharmaceutical composition of claim 1, wherein the at least one miR-10a gene product consists of a sequence having at least 90% identity to SEQ ID: 28 and/or SEQ ID: 322.

6. The pharmaceutical composition of claim 1, wherein the at least one miR-10a gene product comprises a sequence having at least 95% identity to SEQ ID: 28 and/or SEQ ID: 322.

7. The pharmaceutical composition of claim 1, wherein the at least one miR-10a gene product is synthetic pre-miR-10a.

8. A pharmaceutical composition for treating a subject exhibiting a cancer and/or a myeloproliferative disorder associated with overexpression of a transcription factor gene product from the homeobox gene family (HOXA1), wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of: acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), multiple myeloma (MM), and chronic myelogenous leukemia (CML), the composition comprising an effective amount of at least one miR-10a gene product and a pharmaceutically-acceptable carrier, wherein the at least one miR-10a gene product binds to, and decreases expression of, the HOXA1 gene product in the subject, wherein the at least one miR-10a gene product is produced recombinantly, and wherein the subject has been diagnosed with acute myeloid leukemia (AML).

9. The pharmaceutical composition of claim 8, wherein the at least one miR-10a gene product comprises a nucleotide sequence that is complementary to a nucleotide sequence in the HOXA1 gene product.

10. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition further comprises at least one anti-cancer agent.

11. The pharmaceutical composition of claim 10, wherein the at least one anti-cancer agent is selected from the group consisting of: cytidine arabinoside, methotrexate, vincristine, etoposide (VP-16), doxorubicin (adriamycin), cisplatin (CDDP), dexamethasone, arglabin, cyclophosphamide, sarcolysin, methyInitrosourea, fluorouracil, 5-fluorouracil (5FU), vinblastine, camptothecin, actinomycin-D, mitomycin C, hydrogen peroxide, oxaliplatin, irinotecan, topotecan, leucovorin, carmustine, streptozocin, CPT-11, taxol, tamoxifen, dacarbazine, rituximab, daunorubicin, 1-.beta.-D-arabinofuranosylcytosine, imatinib, fludarabine, docetaxel, and FOLFOX4.

12. The pharmaceutical composition of claim 8, wherein the at least one miR-10a gene product consists of a sequence having at least 90% identity to SEQ ID: 28 and/or SEQ ID: 322.

13. The pharmaceutical composition of claim 8, wherein the at least one miR-10a gene product comprises a sequence having at least 95% identity to SEQ ID: 28 and/or SEQ ID: 322.

14. The pharmaceutical composition of claim 8, wherein the at least one miR-10a gene product is synthetic pre-miR-10a.

Details for Patent 8,865,885

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2026-03-20
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Free Forever Trial 2026-03-20
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 2017-06-22 ⤷  Free Forever Trial 2026-03-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Merck
Express Scripts
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.